Hi Ajostu. Unfortunately I can’t make it to the AGM…but I would love to know:
-Neuren has regularly stated they understand the extent of resources required to ensure trofinetide is commercialised as quickly as possible. Does Neuren favour a licensing approach or would an outright sale of Neuren also be considered?
-What has Leerink been instructed to undertake?
-Current cash projects show Neuren will need cash by the end of the year. Is it expected that a deal will be done before a more typical capital raise is required?
-Is Neuren intending to fill the role vacated by Joe Horrigan?
-Did Neuren apply for Breakthrough Therapy Status for Fragile X?
-Has Neuren imposed any social media restrictions on participants in the Rett Phase 2b trial?
-What is the next step for NNZ – 2591 and when will that occur?
AGM questions, page-2
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.97 |
Change
0.070(0.35%) |
Mkt cap ! $2.552B | |||
| Open | High | Low | Value | Volume |
| $20.22 | $20.44 | $19.85 | $4.194M | 209.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2772 | $19.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.99 | 3310 | 1 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |